John Paul Waymack
Chief Tech/Sci/R&D Officer bei MOLECULIN BIOTECH, INC.
Profil
John Paul Waymack was the founder of Purple Biotech Ltd.
which was founded in 1968, where he held the title of Chief Medical Officer from 2019 to 2020.
He currently holds positions as Director at Pam-Bio Ltd.
and Senior Chief Medical Officer at Moleculin Biotech, Inc. Dr. Waymack's former positions include Chairman & Chief Medical Officer at Kitov Pharmaceuticals Ltd., Associate Professor at the University of Medicine & Dentistry of New Jersey, Associate Professor at The University of Texas at Austin, and Chief Surgical Research at The United States Army Medical Service Corps.
Aktive Positionen von John Paul Waymack
| Unternehmen | Position | Beginn |
|---|---|---|
| MOLECULIN BIOTECH, INC. | Chief Tech/Sci/R&D Officer | - |
Pam-Bio Ltd.
 Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Director/Board Member | - |
Ehemalige bekannte Positionen von John Paul Waymack
| Unternehmen | Position | Ende |
|---|---|---|
| PURPLE BIOTECH LTD | Founder | 09.01.2020 |
| University of Medicine & Dentistry of New Jersey | Corporate Officer/Principal | - |
| The United States Army Medical Service Corps | Corporate Officer/Principal | - |
Kitov Pharmaceuticals Ltd.
 Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Chairman | - |
| The University of Texas at Austin | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PURPLE BIOTECH LTD | Health Technology |
| MOLECULIN BIOTECH, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| The United States Army Medical Service Corps | |
Kitov Pharmaceuticals Ltd.
Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Distribution Services |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Health Technology |
